BlossomHill Therapeutics, Inc. reported a sharp increase in second-quarter research spending as the newly listed biotechnology company expanded clinical development of its lead cancer program and prepared additional drug candidates for later-stage testing. Research and development expense reached $21.4 million for the three months ended June 30, 2026, compared with $12.5 million in the year-earlier quarter, an increase of roughly 70%. General and administrative expense more than doubled to $3.3 million from $1.6 million, lifting total operating expense to $24.7 million from $14.1 million. The higher cost base pushed the quarterly net loss to $23.8 million, compared with $13.2 million in the second quarter of 2025.

The results offer an early view of the financial profile investors will be evaluating following BlossomHill’s initial public offering in August. The San Diego-based company is still at the clinical-development stage, so near-term financial performance is driven primarily by research investment, clinical-trial execution and available capital rather than commercial revenue. For that reason, the composition of R&D spending, the company’s cash runway and the timing of its pipeline milestones are central to assessing how quickly the business is deploying the money raised from public investors.

BlossomHill’s detailed quarterly filing shows that the increase in R&D was concentrated in its most advanced programs. External spending on BH-30643 rose to approximately $9.0 million in the second quarter from $3.8 million a year earlier. The company attributed the increase primarily to growth in clinical-trial enrollment and activated study sites, as well as higher manufacturing costs associated with development of the drug. External costs for BH-30236 increased to about $2.0 million from $1.3 million. Spending on preclinical candidate BH-501284 climbed to roughly $2.0 million from only $61,000 a year earlier as BlossomHill funded manufacturing and other IND-enabling work.

Internal development costs also moved higher. Personnel-related R&D expense totaled about $5.7 million in the quarter, compared with $4.9 million a year earlier, while facilities, overhead and other internal R&D costs rose to $1.7 million from about $1.0 million. The figures show BlossomHill increasing both outsourced program spending and the internal infrastructure needed to manage a broader clinical-development effort. The company also reduced spending on some earlier discovery work as capital shifted toward its more advanced drug candidates.

The trend is even more pronounced on a six-month basis. R&D expense totaled $41.3 million for the first half of 2026, compared with $22.1 million in the comparable 2025 period, an increase of approximately 87%. External costs attributed specifically to BH-30643 reached $18.5 million in the first six months of the year, more than triple the $5.6 million recorded a year earlier. BH-501284 spending reached $2.6 million, compared with $61,000 in the first half of 2025. Total operating expenses for the six-month period rose to $46.8 million from $25.6 million, and BlossomHill’s net loss widened to $44.8 million from $23.7 million.

The expanding cost base coincides with a period of unusually active clinical and regulatory development for BlossomHill. Its lead program, BH-30643, is an investigational oral, non-covalent, macrocyclic and mutant-selective EGFR inhibitor being developed for EGFR-mutant non-small cell lung cancer. The compound is being tested in the global Phase 1/2 SOLARA study, which the company says spans more than 40 sites across 10 countries. Development is initially focused in part on patients whose tumors carry the EGFR C797S resistance mutation after treatment with third-generation EGFR tyrosine kinase inhibitors.

That program produced a significant clinical update shortly before the earnings release. On September 15, BlossomHill reported data from patients with C797S-positive resistance showing a 45% objective response rate, with 18 of 40 evaluable patients achieving either confirmed or ongoing unconfirmed partial responses. The company reported an 88% disease-control rate, while 25 of the 40 patients remained on treatment at the efficacy follow-up, with a median follow-up of 6.9 months. Those findings were presented at the IASLC 2026 World Conference on Lung Cancer.

The safety dataset included 174 patients treated at expansion doses of 40 milligrams, 50 milligrams or 60 milligrams twice daily. BlossomHill reported treatment-related dose reductions in 9% of those patients and treatment-related discontinuations in 3%. The company cautions, as is customary for early-stage clinical studies, that preliminary and interim results can change with longer follow-up and may not predict outcomes in larger or later-stage trials. The FDA granted BH-30643 Fast Track designation in August for advanced or metastatic C797S-positive NSCLC following prior treatment with a third-generation EGFR inhibitor.

The development plan creates a relatively dense sequence of catalysts over the next year. BlossomHill expects an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 to discuss a recommended Phase 2 dose and a possible accelerated-approval pathway in C797S-positive disease. The company plans to dose the first patient in an anticipated pivotal Phase 2 trial during the first quarter of 2027. Updated Phase 1 data, including additional information on response durability in C797S-positive patients, are expected in the first half of 2027, followed later in the year by additional data in TKI-naive patients and initial results from a chemotherapy-combination cohort.

BlossomHill is simultaneously advancing two additional programs that contributed to the rising R&D bill. BH-501284 is a preclinical, non-covalent pan-KRAS Switch II inhibitor designed around a new chemical scaffold. The company presented its first preclinical data for the program at the American Association for Cancer Research annual meeting earlier this year and is targeting an Investigational New Drug submission in the first quarter of 2027. Spending on that program has risen rapidly as BlossomHill funds manufacturing and IND-enabling studies needed before human testing can begin.

BH-30236, meanwhile, is an investigational macrocyclic CDC-like kinase inhibitor being evaluated in relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. BlossomHill presented initial clinical findings from the ongoing first-in-human Phase 1/1b trial at the European Hematology Association Congress in June, including early safety observations and signs of anti-leukemic activity. The company expects to provide updated Phase 1 safety and activity data during the first half of 2027. The presence of two clinical-stage programs and a third candidate approaching an IND filing helps explain why expenses are moving higher across both direct program costs and staffing.

The financial counterweight to that expanding development program is BlossomHill’s August IPO. The company had $95.4 million of cash and cash equivalents on June 30, down from $136.7 million at the end of 2025. After the quarter closed, BlossomHill sold 10,516,240 shares in its initial public offering, including the partial exercise of the underwriters’ over-allotment option, for approximately $168.3 million in gross proceeds. The original offering was priced at $16 per share and marked the company’s transition to Nasdaq trading under the ticker BLSM.

Management believes the June-end cash balance combined with IPO proceeds will be sufficient to fund operations into the second quarter of 2028. That projection is important because it extends the expected financing horizon beyond several of the company’s currently identified clinical and regulatory milestones. It does not, however, eliminate financing risk. BlossomHill notes in its regulatory disclosures that drug development and clinical testing are costly and unpredictable, and that the timing, scope and outcome of studies can materially affect capital requirements. The company had accumulated a deficit of approximately $179.8 million as of June 30 and has incurred losses and negative operating cash flows since inception.

The quarterly loss per share was $8.75 on both a basic and diluted basis, compared with $5.51 a year earlier. That comparison should be viewed in the context of the IPO occurring after the end of the quarter. The weighted-average common-share count used for the second-quarter calculation largely reflects the company’s pre-IPO capitalization, while the August offering materially increased shares outstanding. Future per-share loss calculations will therefore be based on a significantly different capital structure even if the company’s absolute operating expenses remain elevated.

General and administrative costs are also beginning to reflect the transition from a private biotechnology company to a public issuer. Second-quarter G&A expense of $3.3 million was more than twice the year-earlier level, with BlossomHill citing higher legal costs, personnel expense and overhead. For the first six months of 2026, G&A expense rose to $5.5 million from $3.5 million. Added public-company reporting, governance, investor-relations and compliance requirements can keep that category elevated independently of scientific development spending.

For the coming quarters, the financial issue is therefore less whether BlossomHill’s spending continues to rise than whether that spending produces the planned clinical and regulatory milestones within the cash runway management has outlined. The SOLARA expansion, an FDA discussion over Phase 2 development, a potential pivotal trial, the planned BH-501284 IND submission and further BH-30236 data all fall inside the company’s current funding horizon. Delays, larger trials, manufacturing requirements or additional development programs could alter that balance.

BlossomHill’s second-quarter results accordingly present the profile typical of an early public-stage biotechnology company moving from discovery toward more capital-intensive clinical execution: losses are widening, R&D is accelerating and the near-term investment case is tied heavily to clinical progress rather than conventional earnings metrics. The August IPO gives the company a larger financial cushion to pursue those programs. The next phase will test whether the increase in research spending can translate into durable clinical evidence, regulatory progress and a clearer path toward later-stage development for its lead oncology assets.